JP2010503674A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010503674A5 JP2010503674A5 JP2009528287A JP2009528287A JP2010503674A5 JP 2010503674 A5 JP2010503674 A5 JP 2010503674A5 JP 2009528287 A JP2009528287 A JP 2009528287A JP 2009528287 A JP2009528287 A JP 2009528287A JP 2010503674 A5 JP2010503674 A5 JP 2010503674A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- alkenyl
- alkynyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000001072 heteroaryl group Chemical group 0.000 claims description 56
- 125000003107 substituted aryl group Chemical group 0.000 claims description 48
- 125000000623 heterocyclic group Chemical group 0.000 claims description 42
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 36
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 36
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 36
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 36
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 36
- 150000001875 compounds Chemical class 0.000 claims description 35
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 34
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 33
- -1 2,3-dihydro-benzo [1,4] dioxinyl Chemical group 0.000 claims description 28
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 24
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 24
- 125000001188 haloalkyl group Chemical group 0.000 claims description 24
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 125000001475 halogen functional group Chemical group 0.000 claims description 22
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 18
- 125000003342 alkenyl group Chemical group 0.000 claims description 16
- 125000000539 amino acid group Chemical group 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 125000003282 alkyl amino group Chemical group 0.000 claims description 14
- 125000005907 alkyl ester group Chemical group 0.000 claims description 14
- 125000000304 alkynyl group Chemical group 0.000 claims description 14
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- 125000002947 alkylene group Chemical group 0.000 claims description 8
- 230000033115 angiogenesis Effects 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 239000000651 prodrug Substances 0.000 claims description 8
- 229940002612 prodrug Drugs 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000012453 solvate Substances 0.000 claims description 8
- 229920003169 water-soluble polymer Polymers 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 6
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims description 5
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 125000005955 1H-indazolyl group Chemical group 0.000 claims description 2
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 claims description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 235000010290 biphenyl Nutrition 0.000 claims description 2
- 239000004305 biphenyl Substances 0.000 claims description 2
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 claims description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 description 14
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 0 *c1n[s]c(*)c1-c1cc(OP(O)(O)=O)c(*)cc1 Chemical compound *c1n[s]c(*)c1-c1cc(OP(O)(O)=O)c(*)cc1 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000004854 thiadizolyl group Chemical group 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84455006P | 2006-09-14 | 2006-09-14 | |
| PCT/US2007/019905 WO2008033449A2 (en) | 2006-09-14 | 2007-09-13 | Compounds for the treatment of angiogenesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010503674A JP2010503674A (ja) | 2010-02-04 |
| JP2010503674A5 true JP2010503674A5 (enExample) | 2010-10-21 |
Family
ID=39092063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009528287A Withdrawn JP2010503674A (ja) | 2006-09-14 | 2007-09-13 | 血管形成治療用化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20100093670A1 (enExample) |
| EP (1) | EP2059250A2 (enExample) |
| JP (1) | JP2010503674A (enExample) |
| AU (1) | AU2007294752A1 (enExample) |
| CA (1) | CA2662554A1 (enExample) |
| WO (1) | WO2008033449A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI297335B (en) | 2001-07-10 | 2008-06-01 | Synta Pharmaceuticals Corp | Taxol enhancer compounds |
| TWI252847B (en) | 2001-07-10 | 2006-04-11 | Synta Pharmaceuticals Corp | Synthesis of taxol enhancers |
| TWI332943B (en) | 2001-07-10 | 2010-11-11 | Synta Pharmaceuticals Corp | Taxol enhancer compounds |
| TWI330079B (en) | 2003-01-15 | 2010-09-11 | Synta Pharmaceuticals Corp | Treatment for cancers |
| ES2430373T3 (es) | 2004-06-23 | 2013-11-20 | Synta Pharmaceuticals Corp. | Sales de bis(tio-hidrazida amida) para tratamiento de cánceres |
| NZ562572A (en) | 2005-04-15 | 2011-01-28 | Synta Pharmaceuticals Corp | Combination cancer therapy with BIS (thiohydrazide) amide compounds |
| TW200735866A (en) * | 2005-11-18 | 2007-10-01 | Synta Pharmaceuticals Corp | Compounds for the treatment of proliferative disorders |
| WO2008024303A2 (en) | 2006-08-21 | 2008-02-28 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
| JP2010502616A (ja) | 2006-08-31 | 2010-01-28 | シンタ ファーマシューティカルズ コーポレーション | 癌を治療するためのビス（チオヒドラジドアミド）の組み合わせ |
| BR112012026644A2 (pt) * | 2010-04-23 | 2017-12-19 | Kineta Inc | compostos antivirais |
| JP6524069B2 (ja) * | 2014-04-30 | 2019-06-05 | 日本カーバイド工業株式会社 | オキシラン化合物及びそれを用いた含窒素複素環式化合物を製造する方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7705027B2 (en) * | 2003-02-11 | 2010-04-27 | Vernalis (Cambridge) Limited | Isoxazole compounds as inhibitors of heat shock proteins |
| AR045595A1 (es) * | 2003-09-04 | 2005-11-02 | Vertex Pharma | Composiciones utiles como inhibidores de proteinas quinasas |
| KR100544347B1 (ko) * | 2003-12-11 | 2006-01-23 | 한국생명공학연구원 | 디아릴이소옥사졸계 화합물을 유효성분으로 함유하는 암 예방 및 치료용 약학적 조성물 |
| EP1919882A2 (en) * | 2005-02-17 | 2008-05-14 | Synta Pharmaceuticals Corporation | Isoxazole combretastatin derivatives for the treatment of proliferative disorders |
-
2007
- 2007-09-13 WO PCT/US2007/019905 patent/WO2008033449A2/en not_active Ceased
- 2007-09-13 AU AU2007294752A patent/AU2007294752A1/en not_active Abandoned
- 2007-09-13 US US12/310,950 patent/US20100093670A1/en not_active Abandoned
- 2007-09-13 EP EP07838160A patent/EP2059250A2/en not_active Withdrawn
- 2007-09-13 CA CA002662554A patent/CA2662554A1/en not_active Abandoned
- 2007-09-13 JP JP2009528287A patent/JP2010503674A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010503674A5 (enExample) | ||
| JP2008530240A5 (enExample) | ||
| US20250230181A1 (en) | Pentaaza macrocyclic ring complexes possessing oral bioavailability | |
| EP2125788B9 (en) | Heterocyclic compounds, compositions comprising them and methods of their use | |
| WO2007070598A3 (en) | Nucleotide and oligonucleotide prodrugs | |
| JP2009102342A5 (enExample) | ||
| WO2009095226A3 (en) | NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS | |
| WO2008110585A3 (en) | Compositions and methods for preventing and treating mucositis and weight loss | |
| CA2597430A1 (en) | Isoxazole combretastin derivatives for the treatment of disorders | |
| TN2012000246A1 (en) | Pharmaceutical compositions comprising sigma receptor ligands | |
| WO2012054500A3 (en) | Compositions for drug administration | |
| JP2009519243A5 (enExample) | ||
| MX2009009849A (es) | Derivados de piridazinona sustituida con piperazina utiles como inhibidores de glucano sintasa. | |
| WO2010098600A3 (en) | Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating parkinson's disease using the same | |
| WO2008000421A3 (en) | Thiazolyl urea derivatives as phosphatidylinositol 3-kinase inhibitors | |
| WO2008145524A3 (en) | 4,4-disubstituted piperidine derivatives | |
| JP2011518843A5 (enExample) | ||
| JP2009521470A5 (enExample) | ||
| WO2003031416A3 (en) | [[2-(amino-3,4-dioxo-1cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain | |
| JP2011506393A5 (enExample) | ||
| JP2009515996A5 (enExample) | ||
| MX2007002531A (es) | Derivados novedosos de 3,5-seco-4-norcolestan y usos de los mismos. | |
| JP2007500158A5 (enExample) | ||
| CN104860932A (zh) | 一种吡唑啉酮类化合物及其应用 | |
| JP2019505571A5 (enExample) |